{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT03384238",
            "orgStudyIdInfo": {
                "id": "IRB-42237"
            },
            "secondaryIdInfos": [
                {
                    "id": "NCI-2017-01943",
                    "type": "REGISTRY",
                    "domain": "CTRP (Clinical Trial Reporting Program)"
                },
                {
                    "id": "PANC0028",
                    "type": "OTHER",
                    "domain": "OnCore"
                },
                {
                    "id": "R01CA190306",
                    "type": "NIH",
                    "link": "https://reporter.nih.gov/quickSearch/R01CA190306"
                }
            ],
            "organization": {
                "fullName": "Stanford University",
                "class": "OTHER"
            },
            "briefTitle": "Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery",
            "officialTitle": "A Phase I/II Study Evaluating the Safety and Pharmacokinetics of Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Pancreas Cancer During Surgical Procedures",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "panitumumab-in-patients-with-pancreatic-cancer-undergoing-surgery"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-01",
            "overallStatus": "RECRUITING",
            "startDateStruct": {
                "date": "2018-02-07",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-03",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-09",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2017-12-19",
            "studyFirstSubmitQcDate": "2017-12-23",
            "studyFirstPostDateStruct": {
                "date": "2017-12-27",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-01-16",
            "lastUpdatePostDateStruct": {
                "date": "2024-01-17",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR_INVESTIGATOR",
                "investigatorFullName": "Eben Rosenthal",
                "investigatorTitle": "Professor of Otolaryngology",
                "investigatorAffiliation": "Stanford University"
            },
            "leadSponsor": {
                "name": "Eben Rosenthal",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "National Cancer Institute (NCI)",
                    "class": "NIH"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This phase I/II trial studies the side effects and best dose of panitumumab-IRDye800 and to see how well it works in finding cancer in patients with pancreatic cancer who are undergoing surgery. Panitumumab-IRDye800 is a combination of the antibody drug panitumumab and IRDye800CW, an investigational dye that can be seen using a special camera. Panitumumab-IRDye800 may attach to tumor cells and make them more visible during surgery in patients with pancreatic cancer.",
            "detailedDescription": "PRIMARY OBJECTIVES:\n\nI. To determine the optimal dose of panitumumab-IRDye800 in identifying pancreatic cancer compared to surrounding normal tissue in the ex vivo setting as measured by tumor to background ratio.\n\nSECONDARY OBJECTIVES:\n\nI. Determine the safety and tolerability of the panitumumab-IRDye800 as an imaging agent in subjects undergoing resection of pancreatic cancer.\n\nII. Determine whether metastatic lesions, positive lymph node, or residual disease can be detected by near-infrared (NIR) fluorescence imaging with panitumumab-IRDye800 but not by white light.\n\nOUTLINE: This is a phase I, dose-escalation study of panitumumab-IRDye800 followed by a phase II study.\n\nPatients receive a loading dose of panitumumab intravenously (IV) over 60 minutes, and after 15 minutes of observation, patients then receive panitumumab-IRDye800 IV over 60 minutes on day 0. Patients then undergo surgical resection 2-5 days after panitumumab-IRDye800 administration with imaging using the Novadaq SPY/LUNA, Novadaq IR9000 fluorescence imaging system with open field handheld fluorescence imaging camera, and/or pinpoint endoscopic fluorescence imaging camera, and SurgVision Explorer Air multi spectral fluorescence reflectance system.\n\nAfter completion of study treatment, patients are followed up at 15 and 30 days."
        },
        "conditionsModule": {
            "conditions": [
                "Pancreatic Adenocarcinoma"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "DIAGNOSTIC",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 27,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Cohort 1a",
                    "type": "EXPERIMENTAL",
                    "description": "A test/loading dose of 100 mg of unlabeled Panitumumab (fixed dose) will be administered via a 60 minute IV infusion prior to infusion of the Panitumumab IRDye800. Cohort 1a will receive 25 mg of Panitumumab IRDye800 with a 100 mg unlabeled test/loading dose of Panitumumab. The surgical resection will then occur 2 to 5 days after infusion. Intraoperative imaging will be performed using the intraoperative optical imaging devices",
                    "interventionNames": [
                        "Procedure: Fluorescence Imaging",
                        "Biological: Panitumumab",
                        "Drug: Panitumumab-IRDye800"
                    ]
                },
                {
                    "label": "Cohort 1b",
                    "type": "EXPERIMENTAL",
                    "description": "Cohort 1b will receive 50 mg of Panitumumab IRDye800 with a 100 mg unlabeled test/loading dose of Panitumumab. A test/loading dose of 100 mg of unlabeled Panitumumab (fixed dose) will be administered via a 60 minute IV infusion prior to infusion of the Panitumumab IRDye800. The surgical resection will then occur 2 to 5 days after infusion. Intraoperative imaging will be performed using the intraoperative optical imaging devices",
                    "interventionNames": [
                        "Procedure: Fluorescence Imaging",
                        "Biological: Panitumumab",
                        "Drug: Panitumumab-IRDye800"
                    ]
                },
                {
                    "label": "Cohort 1c",
                    "type": "EXPERIMENTAL",
                    "description": "Cohort 1c will receive 75 mg of Panitumumab IRDye800 with a 100 mg unlabeled test/loading dose of Panitumumab.A test/loading dose of 100 mg of unlabeled Panitumumab (fixed dose) will be administered via a 60 minute IV infusion prior to infusion of the Panitumumab IRDye800. The surgical resection will then occur 2 to 5 days after infusion. Intraoperative imaging will be performed using the intraoperative optical imaging devices",
                    "interventionNames": [
                        "Procedure: Fluorescence Imaging",
                        "Biological: Panitumumab",
                        "Drug: Panitumumab-IRDye800"
                    ]
                },
                {
                    "label": "Cohort 1d",
                    "type": "EXPERIMENTAL",
                    "description": "Cohort 1d will receive a 50 mg dose of Panitumumab IRDye800 and no test/loading dose. A test/loading dose of 100 mg of unlabeled Panitumumab (fixed dose) will be administered via a 60 minute IV infusion prior to infusion of the Panitumumab IRDye800. The surgical resection will then occur 2 to 5 days after infusion. Intraoperative imaging will be performed using the intraoperative optical imaging devices",
                    "interventionNames": [
                        "Procedure: Fluorescence Imaging",
                        "Biological: Panitumumab",
                        "Drug: Panitumumab-IRDye800"
                    ]
                },
                {
                    "label": "Cohort 2- Dose Expansion",
                    "type": "EXPERIMENTAL",
                    "description": "Cohort 2 will receive the optimal dose of Panitumumab-IRDye800 as determined in Cohort 1",
                    "interventionNames": [
                        "Procedure: Fluorescence Imaging",
                        "Biological: Panitumumab",
                        "Drug: Panitumumab-IRDye800"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "PROCEDURE",
                    "name": "Fluorescence Imaging",
                    "description": "Undergo fluorescence imaging",
                    "armGroupLabels": [
                        "Cohort 1a",
                        "Cohort 1b",
                        "Cohort 1c",
                        "Cohort 1d",
                        "Cohort 2- Dose Expansion"
                    ]
                },
                {
                    "type": "BIOLOGICAL",
                    "name": "Panitumumab",
                    "description": "Given IV",
                    "armGroupLabels": [
                        "Cohort 1a",
                        "Cohort 1b",
                        "Cohort 1c",
                        "Cohort 1d",
                        "Cohort 2- Dose Expansion"
                    ],
                    "otherNames": [
                        "ABX-EGF",
                        "ABX-EGF Monoclonal Antibody",
                        "ABX-EGF, Clone E7.6.3",
                        "MoAb ABX-EGF",
                        "Monoclonal Antibody ABX-EGF",
                        "Vectibix"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Panitumumab-IRDye800",
                    "description": "Given IV",
                    "armGroupLabels": [
                        "Cohort 1a",
                        "Cohort 1b",
                        "Cohort 1c",
                        "Cohort 1d",
                        "Cohort 2- Dose Expansion"
                    ],
                    "otherNames": [
                        "Panitumumab IRDye 800",
                        "RDye800-Panitumumab Conjugate"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Tumor to background ratio (TBR)",
                    "description": "TBR is defined as fluorescence intensity of tumor tissue compared to that of normal surrounding pancreatic tissue.",
                    "timeFrame": "1 day"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Number of Grade 2 or higher AEs determined to be clinically significant and definitely, probably or possibly related to study drug",
                    "description": "Safety events will be recorded over the 30 day observation period.",
                    "timeFrame": "Up to 30 days"
                },
                {
                    "measure": "Number of positive lymph nodes per participant, not detected by white light",
                    "description": "Determine whether positive lymph nodes can be detected by near-infrared (NIR) fluorescence imaging with Panitumumab-IRDye800 but not by white light.",
                    "timeFrame": "1 day"
                },
                {
                    "measure": "Number of positive resection margins per participant, not detected by white light",
                    "description": "Determine whether residual disease at resection margins can be detected by near-infrared (NIR) fluorescence imaging with Panitumumab-IRDye800 but not by white light.",
                    "timeFrame": "1 day"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Clinically suspected or biopsy-confirmed diagnosis of pancreatic adenocarcinoma\n* Planned standard of care surgery with curative intent for pancreatic adenocarcinoma\n* Life expectancy of more than 12 weeks\n* Karnofsky performance status of at least 70% or Eastern Cooperative Oncology Group (ECOG)/Zubrod level =\\< 1\n* Hemoglobin \\>= 9 gm/dL\n* Platelet count \\>= 100,000/mm\\^3\n* Magnesium \\> the lower limit of normal per institution normal lab values\n* Potassium \\> the lower limit of normal per institution normal lab values\n* Calcium \\> the lower limit of normal per institution normal lab values\n* Thyroid-stimulating hormone (TSH) \\< 13 micro international units/mL\n\nExclusion Criteria:\n\n* Received an investigational drug within 30 days prior to first dose of panitumumab-IRDye800\n* Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); or unstable angina within 6 months prior to enrollment\n* History of infusion reactions to panitumumab or other monoclonal antibody therapies\n* Pregnant or breastfeeding\n* Evidence of corrected QT (QTc) prolongation on pretreatment electrocardiography (ECG) (greater than 440 ms in males or greater than 460 ms in females)\n* Lab values that in the opinion of the physician would prevent surgical resection\n* Patients receiving class IA (quinidine, procainamide) or class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "19 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "gitrialeligibility@stanford.edu gitrialeligibility@stanford.edu",
                    "role": "CONTACT",
                    "phone": "(650) 498-7757",
                    "email": "gitrialeligibility@stanford.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "George Poultsides",
                    "affiliation": "Stanford University",
                    "role": "PRINCIPAL_INVESTIGATOR"
                },
                {
                    "name": "Eben Rosenthal",
                    "affiliation": "Stanford University",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Stanford University, School of Medicine",
                    "status": "RECRUITING",
                    "city": "Palo Alto",
                    "state": "California",
                    "zip": "94304",
                    "country": "United States",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "email": "gitrialeligibility@stanford.edu"
                        },
                        {
                            "name": "George Poultsides",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        },
                        {
                            "name": "Eben Rosenthal",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.44188,
                        "lon": -122.14302
                    }
                }
            ]
        },
        "referencesModule": {
            "references": [
                {
                    "pmid": "32416764",
                    "type": "DERIVED",
                    "citation": "Lu G, van den Berg NS, Martin BA, Nishio N, Hart ZP, van Keulen S, Fakurnejad S, Chirita SU, Raymundo RC, Yi G, Zhou Q, Fisher GA, Rosenthal EL, Poultsides GA. Tumour-specific fluorescence-guided surgery for pancreatic cancer using panitumumab-IRDye800CW: a phase 1 single-centre, open-label, single-arm, dose-escalation study. Lancet Gastroenterol Hepatol. 2020 Aug;5(8):753-764. doi: 10.1016/S2468-1253(20)30088-1. Epub 2020 May 14."
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000000230",
                    "term": "Adenocarcinoma"
                }
            ],
            "ancestors": [
                {
                    "id": "D000002277",
                    "term": "Carcinoma"
                },
                {
                    "id": "D000009375",
                    "term": "Neoplasms, Glandular and Epithelial"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M3585",
                    "name": "Adenocarcinoma",
                    "asFound": "Adenocarcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M13110",
                    "name": "Pancreatic Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M12320",
                    "name": "Neoplasms, Glandular and Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "T4387",
                    "name": "Pancreatic Cancer",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                },
                {
                    "abbrev": "BC19",
                    "name": "Gland and Hormone Related Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000077544",
                    "term": "Panitumumab"
                },
                {
                    "id": "D000000906",
                    "term": "Antibodies"
                },
                {
                    "id": "D000007136",
                    "term": "Immunoglobulins"
                },
                {
                    "id": "D000000911",
                    "term": "Antibodies, Monoclonal"
                }
            ],
            "ancestors": [
                {
                    "id": "D000007155",
                    "term": "Immunologic Factors"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4225",
                    "name": "Antibodies",
                    "asFound": "Use",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1822",
                    "name": "Panitumumab",
                    "asFound": "Carotid",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10184",
                    "name": "Immunoglobulins",
                    "asFound": "Use",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4230",
                    "name": "Antibodies, Monoclonal",
                    "asFound": "Double-",
                    "relevance": "HIGH"
                },
                {
                    "id": "M22554",
                    "name": "Pancrelipase",
                    "relevance": "LOW"
                },
                {
                    "id": "M13114",
                    "name": "Pancreatin",
                    "relevance": "LOW"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "asFound": "Double-",
                    "relevance": "HIGH"
                },
                {
                    "id": "M19117",
                    "name": "Immunoglobulins, Intravenous",
                    "relevance": "LOW"
                },
                {
                    "id": "M10201",
                    "name": "Immunologic Factors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "Gast",
                    "name": "Gastrointestinal Agents"
                }
            ]
        }
    },
    "hasResults": false
}